$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz

$jazz Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-Q Financial Statement

#000123252418000094 Filed on May 08, 2018

Income Statement

Concept	2018 Q1	2017 Q1
Revenue	$444.6M	$376.1M
YoY Change	18.23%	11.92%
Cost Of Revenue	$33.90M	$25.10M
YoY Change	35.06%	7.26%
Gross Profit	$406.9M	$348.6M
YoY Change	16.73%	12.28%
Gross Profit Margin	91.52%	92.7%
Selling, General & Admin	$207.2M	$144.3M
YoY Change	43.64%	12.03%
% of Gross Profit	50.92%	41.38%
Research & Development	$62.67M	$44.93M
YoY Change	39.48%	43.76%
% of Gross Profit	15.4%	12.89%
Depreciation & Amortization	$3.722M	$3.130M
YoY Change	18.91%	23.86%
% of Gross Profit	0.91%	0.9%
Operating Expenses	$356.8M	$239.9M
YoY Change	48.72%	11.67%
Operating Profit	$87.81M	$136.1M
YoY Change	-35.5%	12.36%
Interest Expense	-$20.61M	-$18.84M
YoY Change	9.35%	54.56%
% of Operating Profit	-23.47%	-13.84%
Other Income/Expense, Net		-$1.464M
YoY Change		78.75%
Pretax Income	$65.47M	$115.8M
YoY Change	-43.48%	7.1%
Income Tax	$19.15M	$29.16M
% Of Pretax Income	29.24%	25.17%
Net Earnings	$45.99M	$86.51M
YoY Change	-46.84%	14.11%
Net Earnings / Revenue	10.34%	23.01%
Basic Earnings Per Share	$0.77	$1.44
Diluted Earnings Per Share	$0.75	$1.41
COMMON SHARES
Basic Shares Outstanding	59.93M shares	59.88M shares
Diluted Shares Outstanding	61.18M shares	61.18M shares

Balance Sheet

Concept	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$708.2M	$407.0M
YoY Change	74.0%	-58.49%
Cash & Equivalents	$453.2M	$347.0M
Short-Term Investments	$255.0M	$60.00M
Other Short-Term Assets	$62.87M	$27.05M
YoY Change	132.4%	20.6%
Inventory	$46.38M	$37.65M
Prepaid Expenses	$27.48M	$38.12M
Receivables	$281.4M	$243.0M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.126B	$752.9M
YoY Change	49.61%	-40.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$178.9M	$119.9M
YoY Change	49.21%	38.17%
Goodwill	$960.5M	$899.3M
YoY Change	6.81%	34.02%
Intangibles	$2.953B	$2.999B
YoY Change	-1.52%	122.44%
Long-Term Investments
YoY Change
Other Assets	$22.99M	$17.63M
YoY Change	30.41%	-40.34%
Total Long-Term Assets	$4.161B	$4.063B
YoY Change	2.41%	79.43%
TOTAL ASSETS
Total Short-Term Assets	$1.126B	$752.9M
Total Long-Term Assets	$4.161B	$4.063B
Total Assets	$5.287B	$4.816B
YoY Change	9.79%	36.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$46.93M	$29.14M
YoY Change	61.04%	-10.66%
Accrued Expenses	$240.5M	$183.6M
YoY Change	30.98%	-40.28%
Deferred Revenue	$7.498M
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$45.12M	$136.1M
YoY Change	-66.85%	262.03%
Total Short-Term Liabilities	$375.6M	$392.8M
YoY Change	-4.37%	-1.52%
LONG-TERM LIABILITIES
Long-Term Debt	$1.537B	$1.740B
YoY Change	-11.64%	51.74%
Other Long-Term Liabilities	$192.2M	$128.8M
YoY Change	49.2%	62.62%
Total Long-Term Liabilities	$1.729B	$1.868B
YoY Change	-7.45%	52.44%
TOTAL LIABILITIES
Total Short-Term Liabilities	$375.6M	$392.8M
Total Long-Term Liabilities	$1.729B	$1.868B
Total Liabilities	$2.105B	$2.261B
YoY Change	-6.91%	39.19%
SHAREHOLDERS EQUITY
Retained Earnings	$917.6M	$601.5M
YoY Change	52.55%	148.11%
Common Stock	$1.956B	$1.682B
YoY Change	16.29%	5.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.787B	$1.984B
YoY Change
Total Liabilities & Shareholders Equity	$5.287B	$4.816B
YoY Change	9.79%	36.23%

Cashflow Statement

Concept	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	$45.99M	$86.51M
YoY Change	-46.84%	14.11%
Depreciation, Depletion And Amortization	$3.722M	$3.130M
YoY Change	18.91%	23.86%
Cash From Operating Activities	$167.4M	$164.5M
YoY Change	1.71%	8.5%
INVESTING ACTIVITIES
Capital Expenditures	-$7.100M	-$3.600M
YoY Change	97.22%	-67.86%
Acquisitions
YoY Change
Other Investing Activities	-$45.00M	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$52.15M	-$3.574M
YoY Change	1359.12%	-70.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$34.55M	$13.90M
YoY Change	148.6%	-89.66%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$47.58M	-$181.7M
YoY Change	-73.81%	19.16%
NET CHANGE
Cash From Operating Activities	$167.4M	$164.5M
Cash From Investing Activities	-$52.15M	-$3.574M
Cash From Financing Activities	-$47.58M	-$181.7M
Net Change In Cash	$67.13M	-$20.71M
YoY Change	-424.19%	61.79%
FREE CASH FLOW
Cash From Operating Activities	$167.4M	$164.5M
Capital Expenditures	-$7.100M	-$3.600M
Free Cash Flow	$174.5M	$168.1M
YoY Change	3.76%	3.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001232524
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	59996224	shares
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	Jazz Pharmaceuticals plc
CY2018Q1	dei	Trading Symbol TradingSymbol	JAZZ
CY2017Q4	jazz	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	2181000	USD
CY2018Q1	jazz	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	4053000	USD
CY2017Q4	jazz	Accrued Construction In Progress AccruedConstructionInProgress	2827000	USD
CY2018Q1	jazz	Accrued Construction In Progress AccruedConstructionInProgress	838000	USD
CY2017Q4	jazz	Accrued Interest AccruedInterest	7297000	USD
CY2018Q1	jazz	Accrued Inventory Related Liabilities AccruedInventoryRelatedLiabilities	3223000	USD
CY2017Q4	jazz	Accrued Rebates And Other Sales Deductions AccruedRebatesAndOtherSalesDeductions	81368000	USD
CY2018Q1	jazz	Accrued Interest AccruedInterest	2638000	USD
CY2017Q4	jazz	Accrued Inventory Related Liabilities AccruedInventoryRelatedLiabilities	3002000	USD
CY2018Q1	jazz	Accrued Rebates And Other Sales Deductions AccruedRebatesAndOtherSalesDeductions	88878000	USD
CY2017Q4	jazz	Capital Redemption Reserve CapitalRedemptionReserve	472000	USD
CY2018Q1	jazz	Capital Redemption Reserve CapitalRedemptionReserve	472000	USD
CY2018Q1	jazz	Contract With Customer Liability Cumulative Effect Of New Accounting Principle ContractWithCustomerLiabilityCumulativeEffectOfNewAccountingPrinciple	2240000	USD
CY2017Q1	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	25065000	USD
CY2018Q1	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	33919000	USD
CY2017Q4	jazz	Nonvoting Euro Deferred Shares NonvotingEuroDeferredShares	55000	USD
CY2018Q1	jazz	Nonvoting Euro Deferred Shares NonvotingEuroDeferredShares	55000	USD
CY2018Q1	jazz	Number Of Customers With Significant Accounts Receivable Balance NumberOfCustomersWithSignificantAccountsReceivableBalance	5	Customer
CY2017Q1	jazz	Provision For Losses On Accounts Receivable And Inventory ProvisionForLossesOnAccountsReceivableAndInventory	948000	USD
CY2018Q1	jazz	Provision For Losses On Accounts Receivable And Inventory ProvisionForLossesOnAccountsReceivableAndInventory	590000	USD
CY2017Q1	jazz	Royalties And Contract Revenues RoyaltiesAndContractRevenues	2375000	USD
CY2018Q1	jazz	Royalties And Contract Revenues RoyaltiesAndContractRevenues	3766000	USD
CY2017Q4	jazz	Sales Return Reserve SalesReturnReserve	3651000	USD
CY2018Q1	jazz	Sales Return Reserve SalesReturnReserve	3107000	USD
CY2017Q1	jazz	Stock Issued During Period Employee Plansand Warrants Exercises StockIssuedDuringPeriodEmployeePlansandWarrantsExercises	5676000	USD
CY2018Q1	jazz	Stock Issued During Period Employee Plansand Warrants Exercises StockIssuedDuringPeriodEmployeePlansandWarrantsExercises	10588000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	24368000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	46933000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	224129000	USD
CY2018Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	281424000	USD
CY2017Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	54930000	USD
CY2018Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	40966000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	198779000	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	240544000	USD
CY2017Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	3189000	USD
CY2018Q1	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	4546000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3213000	USD
CY2018Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3597000	USD
CY2017Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	8058000	USD
CY2018Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	7050000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	41203000	USD
CY2018Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	40875000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-140878000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-98768000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-140825000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1935486000	USD
CY2018Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1955756000	USD
CY2017Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	14431000	USD
CY2018Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	14594000	USD
CY2018Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	10617000	USD
CY2017Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	25665000	USD
CY2018Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	53007000	USD
CY2017Q4	us-gaap	Assets Assets	5123672000	USD
CY2018Q1	us-gaap	Assets Assets	5287128000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	968277000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25193000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24303000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	17569000	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25297000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24276000	USD
CY2018Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	708169000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	20635000	USD
CY2017Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	5615000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	1126321000	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	601035000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	601035000	USD
CY2018Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	708169000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	365963000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	346995000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	386035000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	453169000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-18968000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	67134000	USD
CY2018Q1	us-gaap	Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths	600000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	104001000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	88048000	USD
CY2017Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	24733000	USD
CY2018Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	20618000	USD
CY2018Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1875000	USD
CY2017Q4	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	-298000	USD
CY2017Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	7673000	USD
CY2018Q1	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	7144000	USD
CY2017Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	34559000	USD
CY2018Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	38103000	USD
CY2018Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	35154000	USD
CY2017Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-15000000	USD
CY2018Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-15307000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	383472000	USD
CY2018Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	382072000	USD
CY2018Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	386605000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	8618000	USD
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6977000	USD
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7498000	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	16115000	USD
CY2018Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	13641000	USD
CY2018Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	14995000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	3130000	USD
CY2018Q1	us-gaap	Depreciation Depreciation	3722000	USD
CY2017Q4	us-gaap	Derivative Asset Fair Value Gross Asset Including Not Subject To Master Netting Arrangement DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement	17633000	USD
CY2018Q1	us-gaap	Derivative Asset Fair Value Gross Asset Including Not Subject To Master Netting Arrangement DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement	6323000	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	5409000	USD
CY2018Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1120000	USD
CY2017Q4	us-gaap	Derivative Liability Fair Value Gross Liability Including Not Subject To Master Netting Arrangement DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement	5409000	USD
CY2018Q1	us-gaap	Derivative Liability Fair Value Gross Liability Including Not Subject To Master Netting Arrangement DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement	1120000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.44
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.77
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.41
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.75
CY2017Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	1740000	USD
CY2018Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-501000	USD
CY2017Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.252
CY2018Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.292
CY2017Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	7624000	USD
CY2018Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	3668000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	578017000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	641865000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1805577000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	158964000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	207083000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	207837000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	208917000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	211923000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3408566000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3442166000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2830549000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2800301000	USD
CY2017Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1464000	USD
CY2018Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1728000	USD
CY2017Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-82000	USD
CY2018Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-256000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	947537000	USD
CY2018Q1	us-gaap	Goodwill Goodwill	960509000	USD
CY2018Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	12972000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	115832000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	65474000	USD
CY2017Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-161000	USD
CY2018Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-337000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29160000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19146000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5865000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	23136000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8483000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	56591000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	30753000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	14183000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-15743000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	47484000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	27490000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1875000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4258000	USD
CY2018Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3312000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2170000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	3988000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	8174000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	7651000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	10637000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3534000	USD
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1298000	shares
CY2018Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1250000	shares
CY2017Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	3557144000	USD
CY2018Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	3595011000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2979127000	USD
CY2018Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2953146000	USD
CY2017Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-18844000	USD
CY2018Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-20605000	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	24011000	USD
CY2018Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	20063000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	43245000	USD
CY2018Q1	us-gaap	Inventory Net InventoryNet	46384000	USD
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3542000	USD
CY2018Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5083000	USD
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	15692000	USD
CY2018Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	21238000	USD
CY2017Q4	us-gaap	Investments Investments	215000000	USD
CY2018Q1	us-gaap	Investments Investments	255000000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5123672000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5287128000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	293947000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	375619000	USD
CY2017Q4	us-gaap	Long Term Debt LongTermDebt	1581038000	USD
CY2018Q1	us-gaap	Long Term Debt LongTermDebt	1582161000	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	40605000	USD
CY2018Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	45117000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1540433000	USD
CY2018Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1537044000	USD
CY2017Q4	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	0	USD
CY2018Q1	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	57000000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3574000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-47149000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-47575000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-181674000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	164540000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	162359000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	86511000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	45991000	USD
CY2018Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2018Q1	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	41890000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	239913000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	356806000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	136140000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	87807000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	23654000	USD
CY2018Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	23528000	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	76686000	USD
CY2018Q1	us-gaap	Other Assets Current OtherAssetsCurrent	62868000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	16419000	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	22985000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	18112000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	38853000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	17490000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	42057000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-622000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	3204000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	-89000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	458000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	176608000	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	192181000	USD
CY2017Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1405000	USD
CY2018Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-16026000	USD
CY2017Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	13896000	USD
CY2018Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	34546000	USD
CY2017Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	14431000	USD
CY2018Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	14594000	USD
CY2017Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	60000000	USD
CY2018Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	235000000	USD
CY2017Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	3574000	USD
CY2018Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	7149000	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	23182000	USD
CY2018Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	27476000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	5676000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	10588000	USD
CY2017Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	60000000	USD
CY2018Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	195000000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	211283000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	219795000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	170080000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	178920000	USD
CY2018Q1	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-167000	USD
CY2017Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	150000000	USD
CY2018Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2017Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	9023000	USD
CY2018Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	9023000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44928000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	62667000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	917956000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	929050000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	917605000	USD
CY2017Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	376053000	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	444613000	USD
CY2017Q1	us-gaap	Revenues Revenues	376053000	USD
CY2018Q1	us-gaap	Revenues Revenues	444613000	USD
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	373678000	USD
CY2018Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	440847000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	144255000	USD
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	207213000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	25193000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	24303000	USD
CY2017Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	13896000	USD
CY2018Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	34546000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	1877339000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	1983986000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	2713097000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	2786571000	USD
CY2017Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	21577000	USD
CY2018Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	36048000	USD
CY2018Q1	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On First Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary	74400000	USD
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61178000	shares
CY2018Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61178000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59880000	shares
CY2018Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59928000	shares
CY2018Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Risk</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and derivative contracts. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and investments to the extent recorded on the balance sheet.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We manage our foreign currency transaction risk and interest rate risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had foreign exchange forward contracts with notional amounts totaling </font><font style="font-family:inherit;font-size:10pt;">$186.5 million</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the net liability fair value of outstanding foreign exchange forward contracts was </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had interest rate swap contracts with notional amounts totaling </font><font style="font-family:inherit;font-size:10pt;">$300.0 million</font><font style="font-family:inherit;font-size:10pt;">. These outstanding interest rate swap contracts had a net asset fair value of </font><font style="font-family:inherit;font-size:10pt;">$5.4 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">. The counterparties to these contracts are large multinational commercial banks, and we believe the risk of nonperformance is not material.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the U.S., and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding.</font></div></div>
CY2018Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001232524-18-000094-index-headers.html	Edgar Link	pending
0001232524-18-000094-index.html	Edgar Link	pending
0001232524-18-000094.txt	Edgar Link	pending
0001232524-18-000094-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
jazz-20180331.xml	Edgar Link	completed
jazz-20180331.xsd	Edgar Link	pending
jazz-20180331_cal.xml	Edgar Link	unprocessable
jazz-20180331_def.xml	Edgar Link	unprocessable
jazz-20180331_lab.xml	Edgar Link	unprocessable
jazz-20180331_pre.xml	Edgar Link	unprocessable
jazz2018q1doc.htm	Edgar Link	pending
jazzq12018ex102.htm	Edgar Link	pending
jazzq12018ex103.htm	Edgar Link	pending
jazzq12018ex311.htm	Edgar Link	pending
jazzq12018ex312.htm	Edgar Link	pending
jazzq12018ex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz

2018 Q1 Form 10-Q Financial Statement

#000123252418000094 Filed on May 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JAZZ Jazz Pharmaceuticals PLC Stock $jazz

2018 Q1 Form 10-Q Financial Statement

#000123252418000094 Filed on May 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz